Rhythm Pharmaceuticals Inc - RYTM Quarterly EPS earnings growth
The transparency of IMCIVREE trials and management's track record with FDA approvals minimize operational risks, which is supported by the historical quarterly EPS growth on GURU.Markets with a metric value of 24.70. Rhythm Pharmaceuticals (RYTM) ensures stable revenue through lifelong treatment of rare genetic obesity, while sufficient capital offsets potential delays in insurance reimbursements for the drug Setmelanotide.
%20Quarterly%20EPS%20earnings%20growth&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_RYTM_-_Rhythm-Pharmaceuticals_-_Quarterly-EPS-earnings-growth "RYTM rhythmtx.com Quarterly EPS earnings growth (07/04/2022 - 11/13/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Rhythm Corp (RYTM)
- share price and consensus valuation forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- debt and liquidity data:
Debt to Equity Rhythm Pharmaceuticals|RYTM - Long-Term Debt to Equity|Short-Term Debt to Capital Rhythm Pharmaceuticals|RYTM - Company Total Debt Obligations|Debt to Book Capitalization Ratio Rhythm Pharmaceuticals Inc|RYTM - Long-Term Debt Volume|Company Short-Term Debt Rhythm Pharmaceuticals|Quick Liquidity rhythmtx.com
- earnings and valuation multiples indicators:
RYTM - Final Profit|Projected Future Earnings Rhythm Pharmaceuticals|RYTM - Company Value to Net Income|Projected Price to Earnings Rhythm Pharmaceuticals Inc|RYTM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Rhythm Pharmaceuticals Inc|RYTM - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Rhythm Pharmaceuticals|RYTM - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months rhythmtx.com|RYTM - Net earnings per share growth this year|Expected earnings per share growth for next year Rhythm Pharmaceuticals
- sales volume and revenue information:
Analysis of all company metrics:Rhythm Pharmaceuticals
Conservative capital demands absolute transparency regarding operational efficiency and earnings sustainability. This indicator measures quarterly net income per share dynamics, revealing the business's real margins after accounting for inflationary pressure. The orphan drug status of Rhythm Pharmaceuticals (RYTM) minimizes competition, ensuring a stable cash flow. GURU.Markets analysts recommend using the quarterly earnings per share growth chart to assess the scaling of this advantage. The trend of this metric confirms the company's fundamental value.
Competitors of Rhythm Pharmaceuticals (RYTM)
ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Akero Corp|Quarterly EPS earnings growth MTSR|Year-over-year earnings per share growth for the last twelve months MLTX (moonlaketx.com)|Year-over-year earnings per share growth for the last twelve months Crinetics CRNX|NewAmsterdam Pharma Company (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Therapeutics Inc.|MiMedx Group Inc (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rezolute Corp (RZLT)|Year-over-year net earnings per share growth for the last 12 months Lexicon Corp LXRX|Year-over-year earnings per share growth for the last twelve months MBX Biosciences Inc MBX|Year-over-year earnings per one share growth for the last 12 months ALT|Aardvark Therapeutics - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months SGMT (Sagimet Biosciences, Inc.)|BIOA (BioAge Labs Inc.) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Biomea Fusion Corp (BMEA)|Year-over-year net earnings per share growth for the last 12 months QNCX|GUTS (fractyl.com) - Year-over-year earnings per share growth rate for the last twelve months|Quarterly EPS earnings growth VTVT|ATPC (agapeatpgroup.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Pluri PLUR|SYBX - Year-over-year net earnings per share growth for the last 12 months|LPCN: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months MTNB (Matinas BioPharma)|Spruce Biosciences (SPRB) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months GLTO (Galecto Inc)|CTCX (Carmell Corp) - Quarterly EPS earnings growth|LUMO: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ONVO|Quarterly EPS earnings growth radiuspharm.com (RDUS)
